Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BNT-325 by Duality Biologics (Shanghai) for Epithelial Ovarian Cancer: Likelihood of Approval
BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Epithelial Ovarian Cancer. According to...
BNT-325 by Duality Biologics (Shanghai) for Peritoneal Cancer: Likelihood of Approval
BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Peritoneal Cancer. According to GlobalData,...
BNT-325 by Duality Biologics (Shanghai) for Fallopian Tube Cancer: Likelihood of Approval
BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Fallopian Tube Cancer. According to...